Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

Mark C. LanasaDuke University Medical Center, Durham, NC, USACorrespondence[email protected]

Patricia H. DavisDuke University Medical Center, Durham, NC, USA

Michael DattoDuke University Medical Center, Durham, NC, USA

Zhiguo LiDuke University Medical Center, Durham, NC, USA

Jon P. GockermanDuke University Medical Center, Durham, NC, USA

Joseph O. MooreDuke University Medical Center, Durham, NC, USA

Carlos M. DeCastroDuke University Medical Center, Durham, NC, USA

Daphne R. FriedmanDuke University Medical Center, Durham, NC, USA

Louis F. DiehlDuke University Medical Center, Durham, NC, USA

Catherine RehderDuke University Medical Center, Durham, NC, USA

Harry CookEleos, Inc., Omaha, NE, USA

F. Joseph DaughertyEleos, Inc., Omaha, NE, USA

Karen M. B. MattaDuke University Medical Center, Durham, NC, USA

J. Brice WeinbergDuke University Medical Center, Durham, NC, USA;Durham VA Medical Center, Durham, NC, USA

David RizzieriDuke University Medical Center, Durham, NC, USA

Articles from other publishers (9)